Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells

Published:2018-02-26 Issue:4 Volume:81 Page:717-726
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Cui Jie,Wang Min-Cong,Zhang Ya-Min,Ren Ming-Zhi,Wang Shi-Xiong,Nan Ke-Jun,Song Li-Ping

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3539-2/fulltext.html

Reference24 articles.

1. Rafiemanesh H, Mehtarpour M, Khani F, Hesami SM, Shamlou R, Towhidi F, Salehiniya H, Makhsosi BR, Moini A (2016) Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis 8(6):1094–1102. https://doi.org/10.21037/jtd.2016.03.91

2. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792. https://doi.org/10.1056/NEJMoa044238

3. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10(11):760–774. https://doi.org/10.1038/nrc2947

4. Lin Y, Wang X, Jin H (2014) EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 4(5):411–435

5. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32(34):3824–3830. https://doi.org/10.1200/jco.2014.56.7412

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T790M mutation sensitizes non-small cell lung cancer cells to radiation via suppressing SPOCK1;Biochemistry and Biophysics Reports;2024-07

2. Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma;BMC Genomics;2023-04-28

3. Comparative cytotoxicity of 177Lu on various lung cancer cells and in vivo targeting of 177Lu-labeled cetuximab;Journal of Radioanalytical and Nuclear Chemistry;2023-04-26

4. Gefitinib Inhibits Rifampicin-Induced CYP3A4 Gene Expression in Human Hepatocytes;ACS Omega;2022-09-13

5. A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancer;2022-06-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3